Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

BOVINE TISSUE-DERIVED DIETARY SUPPLEMENT MANUFACTURERS, IMPORTERS and cosmetics manufacturers and importers are being urged by FDA to develop "plans for ensuring, with a high degree of certainty, that specific bovine-derived materials" from countries where bovine spongiform encephalopathy (BSE) exists "are not used." In an Aug. 17 open letter to "manufacturers and importers" of dietary supplements and cosmetics, FDA Interim Deputy Commissioner for Operations Linda Suydam alerted companies to the need of avoiding bovine tissues or extracts from countries where BSE, a transmissible, "uniformly fatal" neurological disease, has been reported.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts